Morbus Crohn der DGVS

1136
Leitlinie
149 Rutter MD, Saunders BP, Schofield G et al. Pancolonic indigo carmine
dye spraying for the detection of dysplasia in ulcerative colitis. Gut
2004; 53: 256–260
150 Blackstone MO, Riddell RH, Rogers BH et al. Dysplasia-associated lesion
or mass (DALM) detected by colonoscopy in long-standing ulcerative
colitis: an indication for colectomy. Gastroenterology 1981; 80:
366–374
151 Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the
truth about surveillance colonoscopy in ulcerative colitis? Lancet
1994; 343: 71–74
152 Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate
treatment for adenoma-like dysplastic lesions in chronic ulcerative
colitis. Gastroenterology 1999; 117: 1288–1294; discussion
1488 – 1291
153 Rubin PH, Friedman S, Harpaz N et al. Colonoscopic polypectomy in
chronic colitis: conservative management after endoscopic resection
of dysplastic polyps. Gastroenterology 1999; 117: 1295–1300
154 Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in
inflammatory bowel disease: a clinical, pathologic, and follow-up
study of 89 polyps from 59 patients. Am J Surg Pathol 1998; 22:
275–284
155 Vieth M, Behrens H, Stolte M. Sporadic adenoma in ulcerative colitis:
endoscopic resection is an adequate treatment. Gut 2006; 55:
1151–1155
156 Schneider A, Stolte M. Differential diagnosis of adenomas and dysplastic
lesions in patients with ulcerative colitis. Z Gastroenterol
1993; 31: 653–656
157 Befrits R, Ljung T, Jaramillo E et al. Low-grade dysplasia in extensive,
long-standing inflammatory bowel disease: a follow-up study. Dis
Colon Rectum 2002; 45: 615–620
158 Jess T, Loftus Jr EV, Velayos FS et al. Incidence and prognosis of colorectal
dysplasia in inflammatory bowel disease: a population-based
study from Olmsted County, Minnesota. Inflamm Bowel Dis 2006;
12: 669–676
159 Lim CH, Dixon MF, Vail A et al. Ten year follow up of ulcerative colitis
patients with and without low grade dysplasia. Gut 2003; 52:
1127–1132
160 Ullman T, Croog V, Harpaz N et al. Progression of flat low-grade dysplasia
to advanced neoplasia in patients with ulcerative colitis. Gastroenterology
2003; 125: 1311–1319
161 Eaden J, Abrams K, McKay H et al. Inter-observer variation between
general and specialist gastrointestinal pathologists when grading
dysplasia in ulcerative colitis. J Pathol 2001; 194: 152–157
162 Jeejeebhoy KN, Detsky AS, Baker JP. Assessment of nutritional status.
JPEN J Parenter Enteral Nutr 1990; 14: 193S–196S
163 Lochs H, Dejong C, Hammarqvist F et al. ESPEN Guidelines on Enteral
Nutrition: Gastroenterology. Clin Nutr 2006; 25: 260–274
164 Otley A, Steinhart AH. Budesonide for induction of remission in
Crohn’s disease. Cochrane Database Syst Rev 2005: CD000296
165 Bar-Meir S, Chowers Y, Lavy A et al. Budesonide versus prednisone in
the treatment of active Crohn’s disease. The Israeli Budesonide Study
Group. Gastroenterology 1998; 115: 835–840
166 Caesar I, Gross V, Roth M et al. Treatment of active and postactive ileal
and colonic Crohn’s disease with oral pH-modified-release budesonide.
German Budesonide Study Group. Hepatogastroenterology
1997; 44: 445–451
167 Campieri M, Ferguson A, Doe W et al. Oral budesonide is as effective as
oral prednisolone in active Crohn’s disease. The Global Budesonide
Study Group. Gut 1997; 41: 209–214
168 Escher JC. Budesonide versus prednisolone for the treatment of active
Crohn’s disease in children: a randomized, double-blind, controlled,
multicentre trial. Eur J Gastroenterol Hepatol 2004; 16: 47–54
169 Greenberg GR, Feagan BG, Martin F et al. Oral budesonide for active
Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group.
N Engl J Med 1994; 331: 836–841
170 Gross V, Andus T, Caesar I et al. Oral pH-modified release budesonide
versus 6-methylprednisolone in active Crohn’s disease. German/
Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;
8: 905–909
171 Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active
Crohn’s disease: A meta-analysis of double-blind, placebo-controlled
trials. Clin Gastroenterol Hepatol 2004; 2: 379–388
172 Su C. Outcomes of placebo therapy in inflammatory bowel disease.
Inflamm Bowel Dis 2006; 12: 328–333
173 Prantera C, Lochs H, Campieri M et al. Antibiotic treatment of Crohn’s
disease: results of a multicentre, double blind, randomized, placebocontrolled
trial with rifaximin. Aliment Pharmacol Ther 2006; 23:
1117–1125
174 Colombel JF, Lemann M, Cassagnou M et al. A controlled trial comparing
ciprofloxacin with mesalazine for the treatment of active
Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires
Digestives (GETAID). Am J Gastroenterol 1999; 94:
674–678
175 Goodgame RW, Kimball K, Akram S et al. Randomized controlled trial
of clarithromycin and ethambutol in the treatment of Crohn’s disease.
Aliment Pharmacol Ther 2001; 15: 1861–1866
176 Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled
trial of metronidazole in Crohn’s disease. Gut 1991; 32:
1071–1075
177 Ambrose NS, Allan RN, Keighley MR et al. Antibiotic therapy for treatment
in relapse of intestinal Crohn’s disease. A prospective randomized
study. Dis Colon Rectum 1985; 28: 81–85
178 Blichfeldt P, Blomhoff JP, Myhre E et al. Metronidazole in Crohn’s
disease. A double blind cross-over clinical trial. Scand J Gastroenterol
1978; 13: 123–127
179 Arnold GL, Beaves MR, Pryjdun VO et al. Preliminary study of ciprofloxacin
in active Crohn’s disease. Inflamm Bowel Dis 2002; 8: 10–15
180 Prantera C, Zannoni F, Scribano ML et al. An antibiotic regimen for the
treatment of active Crohn’s disease: a randomized, controlled clinical
trial of metronidazole plus ciprofloxacin. Am J Gastroenterol
1996; 91: 328–332
181 Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy
with clarithromycin, rifabutin, and clofazimine for Crohn’s
disease. Gastroenterology 2007; 132: 2313–2319
182 Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic
picture of attacks of Crohn’s disease. Evolution on prednisolone.
Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives.
Gastroenterology 1990; 98: 811–818
183 Benchimol E, Seow C, Steinhart A et al. Traditional corticosteroids for
induction of remission in Crohn’s disease. Cochrane Database Syst
Rev 2008: CD006792
184 Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction
of remission in Crohn’s disease. Cochrane Database Syst Rev
2007: CD000542
185 Lochs H, Steinhardt HJ, Klaus-Wentz B et al. Comparison of enteral nutrition
and drug treatment in active Crohn’s disease. Results of the
European Cooperative Crohn’s Disease Study. IV. Gastroenterology
1991; 101: 881–888
186 Schutz T, Valentini L, Herbst B et al. ESPEN guidelines on enteral nutrition
– summary. Z Gastroenterol 2006; 44: 683–684
187 Gasche C, Berstad A, Befrits R et al. Guidelines on the diagnosis and
management of iron deficiency and anemia in inflammatory bowel
diseases. Inflamm Bowel Dis 2007; 13: 1545–1553
188 Steinhart AH, Feagan BG, Wong CJ et al. Combined budesonide and
antibiotic therapy for active Crohn’s disease: a randomized controlled
trial. Gastroenterology 2002; 123: 33–40
189 Summers RW, Switz DM, Sessions Jr JT et al. National Cooperative
Crohn’s Disease Study: results of drug treatment. Gastroenterology
1979; 77: 847–869
190 Malchow H, Ewe K, Brandes JW et al. European Cooperative Crohn’s
Disease Study (ECCDS): results of drug treatment. Gastroenterology
1984; 86: 249–266
191 Mielants H, Veys EM, Cuvelier C et al. HLA-B27 related arthritis and
bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in
patients with HLA-B27 related arthritis. J Rheumatol 1985; 12:
294–298
192 Herfarth H, Gross V, Andus T et al. Analysis of the therapeutic efficacy
of different doses of budesonide in patients with active Crohn’s ileocolitis
depending on disease activity and localization. Int J Colorectal
Dis 2004; 19: 147–152
193 Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn’s
disease. Gastroenterology 2006; 130: 650–656
194 Fichera A, Lovadina S, Rubin M et al. Patterns and operative treatment
of recurrent Crohn’s disease: a prospective longitudinal study. Surgery
2006; 140: 649–654
195 Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty
for Crohn’s disease: a systematic review and meta-analysis. Dis
Colon Rectum 2007; 50: 1968–1986
Hoffmann JC et al. Diagnostik und Therapie… Z Gastroenterol 2008; 46: 1094–1146